Jubilant Pharmova Limited (BOM:530019)
India
· Delayed Price · Currency is INR 1,069.20
-9.25 (-0.86%)
At close: Dec 4, 2025
Jubilant Pharmova Revenue
Jubilant Pharmova had revenue of 19.66B INR in the quarter ending September 30, 2025, with 12.22% growth. This brings the company's revenue in the last twelve months to 76.18B, up 10.09% year-over-year. In the fiscal year ending March 31, 2025, Jubilant Pharmova had annual revenue of 72.35B with 7.93% growth.
Revenue (ttm)
76.18B
Revenue Growth
+10.09%
P/S Ratio
2.24
Revenue / Employee
13.73M
Employees
5,547
Market Cap
170.50B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 72.35B | 5.32B | 7.93% |
| Mar 31, 2024 | 67.03B | 4.21B | 6.71% |
| Mar 31, 2023 | 62.82B | 1.52B | 2.47% |
| Mar 31, 2022 | 61.30B | 316.29M | 0.52% |
| Mar 31, 2021 | 60.99B | 1.23B | 2.05% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Reliance Industries | 9,996.29B |
| HDFC Bank | 2,683.70B |
| Bharti Airtel | 1,946.14B |
| Tata Consultancy Services | 2,576.88B |
| ICICI Bank | 1,909.34B |
| State Bank of India | 3,571.95B |
| Infosys | 1,748.84B |
| Bajaj Finance | 406.39B |
Jubilant Pharmova News
- 2 months ago - Jubilant Pharmova subsidiary launches new high-speed isolator-based line at US facility, adds 50% capacity - Business Upturn
- 4 months ago - Jubilant Pharmova receives 4 observations from USFDA after Pre-Approval Inspection at Roorkee facility - Business Upturn
- 4 months ago - Jubilant Food Share Price Target 2022 - ABC Money
- 6 months ago - QSR sector faces rising competition; CLSA cautious on Jubilant and Westlife, positive on Devyani and RBA - Business Upturn
- 1 year ago - Jubilant to buy 40% in Coke bottler's parent for 10k cr - The Times of India
- 1 year ago - Bernstein maintains Outperform rating on Jubilant Foodworks, highlights three pillars to achieve $10 billion market cap - Business Upturn
- 1 year ago - Eagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financial Officer - Benzinga
- 1 year ago - CLSA maintains ‘Underperform’ rating on Jubilant FoodWorks with target price of Rs 445, expecting 26% downside - Business Upturn